Navigating Market Volatility: Top Healthcare Stock Picks and Industry Insights
In times of geopolitical uncertainty and market downturns, the healthcare sector often emerges as a resilient and defensive investment avenue. Leading Australian broker Ord Minnett has identified several local healthcare companies poised for strong performance, even amidst current market turbulence. Their top selections include a mix of established operators and emerging innovators, offering investors a diverse range of opportunities.
Ord Minnett’s Leading Healthcare Recommendations
Ord Minnett’s current favourite healthcare stocks are:
- Regis Healthcare (ASX:REG): An operator of retirement villages and nursing homes. The firm highlights Regis’s strong net cash position and anticipates numerous upcoming events that could positively impact its share price.
- Integral Diagnostics (ASX:IDX): A pathology provider. Integral Diagnostics makes the list due to its robust revenue growth potential and attractive valuation, especially considering its shares have fallen by over 20% year-to-date.
- Sigma Healthcare (ASX:SIG): The owner of Chemist Warehouse. Sigma Healthcare is noted for its multiple avenues for growth and high incremental profit margins.
Medtech Innovation and Emerging Players
Beyond these core recommendations, Ord Minnett also points to advancements in medical technology.
- Echo IQ (ASX:EIQ): This company is focused on commercialising diagnostic tools for the heart, specifically designed to detect aortic stenosis.
However, the broker also cautions that not all areas of the healthcare sector are immune to the broader economic pressures.
Identifying Potential Risks in the Healthcare Supply Chain
Ord Minnett identifies specific segments within the healthcare industry that are more vulnerable to current economic headwinds.
- Pharmaceutical Wholesalers and Pathology Providers: These businesses are considered most exposed to the impacts of rising fuel prices and persistent supply chain disruptions.
The specific companies flagged as being most susceptible include:
- EBOS Group (ASX:EBO)
- Sigma Healthcare (ASX:SIG)
- Paragon Care (ASX:PGC)
- Australian Clinical Labs (ASX:ACL): This pathology provider is singled out as being the most exposed in its segment.
The firm’s analysis points out that these companies often operate their own freight and logistics networks, crucial for activities like medicine distribution and sample transportation. Their ability to immediately pass on increased operational costs, such as fuel and logistics, is limited in the short term. To illustrate this point, EBOS Group anticipates freight costs to reach $182 million in the current financial year, a significant portion, approximately 16%, of its projected operating expenditure.
Ord Minnett’s Full Buy List and Speculative Opportunities
Expanding on their recommendations, Ord Minnett has issued ‘buy’ ratings on a broader range of healthcare companies:
- EBOS Group (ASX:EBO)
- Integral Diagnostics (ASX:IDX)
- Regis Healthcare (ASX:REG)
- Paragon Care (ASX:PGC)
- Trajan Group (ASX:TRJ): A manufacturer of scientific equipment.
Furthermore, Sigma Healthcare’s rating has been upgraded from ‘accumulate’ to a ‘buy’.
For investors with a higher risk tolerance, Ord Minnett also applies ‘speculative buy’ calls to:
- Echo IQ (ASX:EIQ)
- ImpediMed (ASX:IPD): A medical device manufacturer.
- Vitrafy Life Sciences (ASX:VFY): A company involved in cryogenics.
Intriguingly, Ord Minnett has issued a ‘sell’ recommendation for 4D Medical (ASX:4DX), a company focused on lung imaging technology, with a target price of $3. This comes despite the company’s shares experiencing a significant surge of 33% to over $6, reaching a new record high, following news of its ventilation perfusion tool being utilised by the Mayo Clinic.
Previous Market Insights: Resilient Healthcare Stocks
It’s worth noting that other financial institutions have also highlighted the defensive qualities of the healthcare sector. Previously, UBS identified five top healthcare stocks within the S&P ASX 200 that have historically outperformed the broader market during periods of geopolitical and economic crises. These included:
- CSL (ASX:CSL)
- Ramsay Health Care (ASX:RHC)
- Cochlear (ASX:COH)
- ResMed (ASX:RMD)
- Sonic Healthcare (ASX:SHL)
Paradigm Biopharmaceuticals: Nearing a Critical Milestone in Knee Trial
Paradigm Biopharmaceuticals (ASX:PAR) is making significant headway in its pivotal Phase III clinical trial for knee osteoarthritis. Chairman Dr Paul Rennie recently announced that the company is approaching the halfway point in patient recruitment and treatment for the 466 subjects enrolled in the study.
The trial is progressing well, with management expressing confidence in its trajectory. Reaching the 50% recruitment and treatment milestone is particularly important as it triggers an independent review of the blinded data. This interim analysis will provide crucial insights into the trial’s potential success or, in a less favourable scenario, its futility. The study is designed to maximise its chances of a positive outcome.
Having successfully completed three Phase II studies, involving approximately 700 patients treated under real-world conditions, Paradigm’s management is optimistic about the Phase III results. Dr Rennie pointed out that while many drug candidates fail to progress from Phase II to Phase III, Paradigm has already overcome this hurdle and is now in the critical Phase III to New Drug Application (NDA) stage. He suggests that the ability to conduct an interim analysis during Phase III allows for potential “course correction,” such as adjusting recruitment numbers to enhance statistical power, thereby improving the odds of success. The company anticipates releasing the interim analysis in mid-2026, keeping shareholders in anticipation.
Lumos Diagnostics: Awaiting Crucial FDA Decision
Lumos Diagnostics (ASX:LDX) has entered a trading halt as it awaits a significant update regarding its Febridx test for differentiating bacterial and viral infections. The company is seeking a CLIA waiver from the US Food and Drug Administration (FDA).
A CLIA waiver, granted under the Clinical Laboratory Improvements Amendment, signifies that a diagnostic test is deemed simple and carries minimal risk, allowing it to be performed by non-laboratory personnel, such as nurses and receptionists, in various medical settings.
Securing this waiver would dramatically expand the addressable market for Febridx in the United States, projecting an increase to over US$1 billion annually, serving an estimated 80 million patients. While Febridx received FDA clearance in October 2023, it was for ‘moderate to complex’ uses requiring a trained clinician, which represents only about 5% of the potential market. Lumos Diagnostics is expected to announce the outcome of its waiver application imminently, potentially by Friday. Despite a 17% retreat in share price year-to-date, Lumos Diagnostics has experienced remarkable growth over the past year, with its shares soaring by an impressive 1225%.
